RxDoctor Payments Data

Joshua Bain

Family · Anniston, ALNPI 1568109882

Payments from drug & device makers

$4,566in general payments, 2019–2025

Across 175 payments — averaging $26.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • Dexcom, Inc.$1K
  • Kyowa Kirin, Inc.$140
  • Tandem Diabetes Care, Inc.$123
  • Xeris Pharmaceuticals, Inc.$116
  • Corcept Therapeutics$104
  • plus $777 from 18 others

What the payments were for

  • Travel & lodging$1,73838%
  • Food & beverage$2,82762%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,566 in reported general payments places this provider in the 85th percentile of 3,415 family providers in Alabama.

See all family providers in Alabama

Medicare billing

Part B allowed, 2024
$53,062
Medicare patients
340
Services billed
776

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide80$140,599
MounjaroTirzepatide31$59,009
TrulicityDulaglutide22$41,997
JardianceEmpagliflozin29$31,767
RybelsusSemaglutide15$26,946
Fiasp FlextouchInsulin Aspart (Niacinamide)17$17,131
Novolog FlexpenInsulin Aspart20$8,452
Tresiba Flextouch U-100Insulin Degludec12$7,268
VascepaIcosapent Ethyl19$6,668
Lantus SolostarInsulin Glargine,hum.Rec.Anlog22$3,717
Humalog Kwikpen U-100Insulin Lispro19$2,929
Levothyroxine Sodium142$2,167
Nano 2nd Gen Pen NeedlePen Needle, Diabetic16$1,779
Rosuvastatin Calcium34$949
Ezetimibe18$879

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$79$167,54595 claims
Lilly USA, LLCMounjaro, Trulicity$45$101,00653 claims
Boehringer IngelheimJardiance$53$31,76729 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$32$2,167142 claims
AbbVieSynthroid$89$52111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,415 family providers in Alabama.

Other family in Anniston

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →